QQQ   388.34 (-0.38%)
AAPL   189.53 (+0.08%)
MSFT   377.94 (-0.24%)
META   324.66 (-2.27%)
GOOGL   131.96 (-2.24%)
AMZN   146.36 (+0.03%)
TSLA   239.20 (-2.02%)
NVDA   467.57 (-2.87%)
NIO   7.20 (+0.28%)
BABA   74.88 (+0.28%)
AMD   120.90 (-2.38%)
T   16.57 (+1.66%)
F   10.24 (-3.31%)
MU   75.47 (-1.59%)
CGC   0.56 (-0.70%)
GE   121.64 (+2.34%)
DIS   92.49 (-0.01%)
AMC   6.68 (-6.83%)
PFE   30.35 (+0.90%)
PYPL   57.63 (-0.59%)
XOM   102.77 (+0.42%)
QQQ   388.34 (-0.38%)
AAPL   189.53 (+0.08%)
MSFT   377.94 (-0.24%)
META   324.66 (-2.27%)
GOOGL   131.96 (-2.24%)
AMZN   146.36 (+0.03%)
TSLA   239.20 (-2.02%)
NVDA   467.57 (-2.87%)
NIO   7.20 (+0.28%)
BABA   74.88 (+0.28%)
AMD   120.90 (-2.38%)
T   16.57 (+1.66%)
F   10.24 (-3.31%)
MU   75.47 (-1.59%)
CGC   0.56 (-0.70%)
GE   121.64 (+2.34%)
DIS   92.49 (-0.01%)
AMC   6.68 (-6.83%)
PFE   30.35 (+0.90%)
PYPL   57.63 (-0.59%)
XOM   102.77 (+0.42%)
QQQ   388.34 (-0.38%)
AAPL   189.53 (+0.08%)
MSFT   377.94 (-0.24%)
META   324.66 (-2.27%)
GOOGL   131.96 (-2.24%)
AMZN   146.36 (+0.03%)
TSLA   239.20 (-2.02%)
NVDA   467.57 (-2.87%)
NIO   7.20 (+0.28%)
BABA   74.88 (+0.28%)
AMD   120.90 (-2.38%)
T   16.57 (+1.66%)
F   10.24 (-3.31%)
MU   75.47 (-1.59%)
CGC   0.56 (-0.70%)
GE   121.64 (+2.34%)
DIS   92.49 (-0.01%)
AMC   6.68 (-6.83%)
PFE   30.35 (+0.90%)
PYPL   57.63 (-0.59%)
XOM   102.77 (+0.42%)
QQQ   388.34 (-0.38%)
AAPL   189.53 (+0.08%)
MSFT   377.94 (-0.24%)
META   324.66 (-2.27%)
GOOGL   131.96 (-2.24%)
AMZN   146.36 (+0.03%)
TSLA   239.20 (-2.02%)
NVDA   467.57 (-2.87%)
NIO   7.20 (+0.28%)
BABA   74.88 (+0.28%)
AMD   120.90 (-2.38%)
T   16.57 (+1.66%)
F   10.24 (-3.31%)
MU   75.47 (-1.59%)
CGC   0.56 (-0.70%)
GE   121.64 (+2.34%)
DIS   92.49 (-0.01%)
AMC   6.68 (-6.83%)
PFE   30.35 (+0.90%)
PYPL   57.63 (-0.59%)
XOM   102.77 (+0.42%)

VIVUS Stock Price, News & Analysis (NASDAQ:VVUS)

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.26
▼
$0.47
52-Week Range
N/A
Volume
2.03 million shs
Average Volume
1.44 million shs
Market Capitalization
$7.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

VVUS stock logo

About VIVUS Stock (NASDAQ:VVUS)

VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.


VVUS Stock News Headlines

May 25, 2023 | it.tmcnet.com
Metaview announces Answers, the world's first conversational AI for the interview process
October 2, 2022 | marketwatch.com
Why aren’t new drugs that can help you lose weight more widely used? - MarketWatch
November 30, 2023 | Autonomix (Ad)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
October 2, 2022 | morningstar.com
'There's no way that patients are going to be able to afford that.' Why aren't new drugs that can help you lose weight more widely used? - Morningstar
September 23, 2022 | finance.yahoo.com
Erectile Dysfunction Drugs Market to Surpass Around USD 4079.9 Million by 2028, Says Brandessence Market Research - Yahoo Finance
September 16, 2022 | streetinsider.com
Form DEF 14A Catalent, Inc. For: Oct 27 - StreetInsider.com
September 9, 2022 | globenewswire.com
Obesity Management Market Expanding at an Impressive CAGR - GlobeNewswire
August 26, 2022 | finance.yahoo.com
Global Human Reproductive Technology Products and Markets Analysis Report 2022: Data from 2020-2021, Estimates for 2022, and CAGR Projections through 2027 - Yahoo Finance
November 30, 2023 | Autonomix (Ad)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
August 26, 2022 | prnewswire.com
Global Human Reproductive Technology Products and Markets Analysis Report 2022: Data from 2020-2021, Estimates for 2022, and CAGR Projections through 2027 - PR Newswire
August 17, 2022 | stockhouse.com
2022-08-15 | NDAQ:PTPI | Press Release | Petros Pharmaceuticals Inc. - Stockhouse
August 15, 2022 | streetinsider.com
Petros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022 - StreetInsider.com
August 11, 2022 | finance.yahoo.com
Kaléo Announces Executive Appointments and New Government Business Unit - Yahoo Finance
August 5, 2022 | marketscreener.com
Icahn Enterprises L P : Reports Second Quarter 2022 Financial Results - Form 8-K - Marketscreener.com
August 2, 2022 | benzinga.com
Global Cystic Fibrosis Market Report 2022-2030: CFTR Modulators Segment to Dominate the Market - Benzinga
July 31, 2022 | businesswire.com
Global Cystic Fibrosis Market Report 2022: Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts 2020-2030 - ResearchAndMarkets.com - Business Wire
July 26, 2022 | globenewswire.com
Global Achondroplasia Market to Surpass US$ 1100.97 Million by 2030, Says Coherent Market Insights (CMI) - GlobeNewswire
July 14, 2022 | fortune.com
The best stock investing strategy for 2022: Don’t buy the dip, buy the dividend - Fortune
July 5, 2022 | finance.yahoo.com
BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors - Yahoo Finance
July 5, 2022 | streetinsider.com
BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors - StreetInsider.com
June 8, 2022 | benzinga.com
Overweight Treatment Market estimated to surge ahead at a CAGR of 7.9% by the end of 2032 - Persistence M - Benzinga
May 16, 2022 | stockhouse.com
2022-05-16 | NDAQ:PTPI | Press Release | Petros Pharmaceuticals Inc. - Stockhouse
May 6, 2022 | fool.com
Icahn Enterprises (IEP) Q1 2022 Earnings Call Transcript - The Motley Fool
May 3, 2022 | gurufocus.com
Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company's Novel Topical Investigational Treatment for Peyronie's Disease Which Impacts More Than 1 in 10 Men in the US - GuruFocus.com
May 3, 2022 | globenewswire.com
Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company's Novel Topical Investigational Treatment for Peyronie's Disease Which Impacts More Than 1 in 10 Men in the US - GlobeNewswire
April 27, 2022 | gurufocus.com
Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology - GuruFocus.com
April 26, 2022 | finance.yahoo.com
Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology - Yahoo Finance
See More Headlines
Receive VVUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVUS and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/06/2020
Today
11/30/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:VVUS
CUSIP
92855110
CIK
881524
Web
www.vivus.com
Phone
(650) 934-5200
Fax
N/A
Employees
57
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($2.96)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-31,500,000.00
Net Margins
-39.28%
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-12.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.43
Quick Ratio
0.28

Sales & Book Value

Annual Sales
$69.76 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($6.50) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
17,867,000
Free Float
N/A
Market Cap
$7.33 million
Optionable
Optionable
Beta
-0.84
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • John P. Amos
    Chief Executive Officer & Director
  • Mark K. Oki
    Chief Financial & Accounting Officer, Senior VP
  • Santosh T. Varghese
    Chief Medical Officer & Senior Vice President
  • Ted Broman
    Vice President-Chemistry, Manufacturing & Control
  • Tracy Guo
    Vice President-Finance

Key Competitors

View All Competitors














VVUS Stock Analysis - Frequently Asked Questions

How were VIVUS's earnings last quarter?

VIVUS, Inc. (NASDAQ:VVUS) announced its earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.80) by $0.31. The biopharmaceutical company earned $19.63 million during the quarter.

When did VIVUS's stock split?

VIVUS's stock reverse split on Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 10th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of VIVUS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VIVUS investors own include Fulcrum Therapeutics (FULC), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL), Novavax (NVAX), General Electric (GE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Amarin (AMRN), Geron (GERN) and Idera Pharmaceuticals (IDRA).

This page (NASDAQ:VVUS) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -